US2018222968A1PendingUtilityA1
Antibody that binds murine wise protein
Assignee: STOWERS INSTITUTE FOR MEDICAL RESPriority: Jun 14, 2002Filed: Mar 30, 2018Published: Aug 9, 2018
Est. expiryJun 14, 2022(expired)· nominal 20-yr term from priority
A61P 13/12C07K 14/705C07K 14/4702A01K 2227/105C07K 16/30C07K 2317/622C07K 2317/76A61K 48/00A01K 2217/05C07K 2317/626A61K 2039/505A61K 38/00C07K 2317/54C07K 16/18C07K 2317/34C07K 14/47C07K 2317/55C07K 14/575A01K 2217/075
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.
Claims
exact text as granted — not AI-modified1 .- 20 . (canceled)
21 . An isolated antibody that specifically binds to the contiguous amino acids of SEQ ID NO: 91.
22 . The isolated antibody of claim 1 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a Fv fragment of an antibody, a Fab fragment of an antibody, a F(ab′)2 fragment of an antibody, a recombinant single chain Fv fragment (scFv), a diabody, a triabody, and a tetrabody.
23 . The isolated antibody of claim 2 , wherein the antibody is a monoclonal antibody.
24 . An isolated antibody that specifically binds to the contiguous amino acids of SEQ ID NO: 93.
25 . The isolated antibody of claim 4 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a Fv fragment of an antibody, a Fab fragment of an antibody, a F(ab′)2 fragment of an antibody, a recombinant single chain Fv fragment (scFv), a diabody, a triabody, and a tertrabody.
26 . The isolated antibody of claim 2 , wherein the antibody is a monoclonal antibody.
27 . An isolated antibody that specifically binds to the contiguous amino acids of SEQ ID NO: 95.
28 . The isolated antibody of claim 6 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a Fv fragment of an antibody, a Fab fragment of an antibody, a F(ab′)2 fragment of an antibody, a recombinant single chain Fv fragment (scFv), a diabody, a triabody, and a tertrabody.
29 . The isolated antibody of claim 8 , wherein the antibody is a monoclonal antibody.Join the waitlist — get patent alerts
Track US2018222968A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.